Source.
....such concerns are unlikely to dampen desire among drugmakers to define, and then seek to treat, low female libido.
Besides Germany's Boehringer's big hope flibanserin -- which in a six-month trial increased the number of satisfying sexual events to an average 4.5 per month from 2.8 in American women, compared with an average of 3.7 for those taking placebo -- there are trials looking at the effects of a testosterone skin gel Libigel, from U.S. drug firm BioSante, on women's desire. Procter & Gamble's Intrinsa testosterone patches are already licensed for female sexual dysfunction in Europe
